Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Background Lebrikizumab monotherapy significantly improved signs and symptoms in patients with moderate-to-severe atopic dermatitis (AD) in phase 3 Advocate1 and ADvocate2 studies.Objective To evaluate improvements in patient-reported symptoms and quality-of-life (QoL) measures by Eczema Area and Se...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Journal of Dermatological Treatment
Subjects:
Atopic dermatitis
lebrikizumab
Eczema Area and Severity Index
quality of life
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2442720
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2442720

Similar Items